List of Chapters/Sections(Table Of Content)
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Biologics and Biosimilars Revenue
1.4 Market Analysis by Type
1.4.1 Global Biologics and Biosimilars Market Size Growth Rate by Type: 2021 VS 2027
1.4.2 Monoclonal Antibodies
1.4.3 Interferon
1.4.4 Erythropoietin
1.4.5 Insulin
1.4.6 Vaccines
1.5 Market by Application
1.5.1 Global Biologics and Biosimilars Market Share by Application: 2022-2027
1.5.2 Tumor
1.5.3 Diabetes
1.5.4 Cardiovascular
1.5.5 Hemophilia
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Biologics and Biosimilars Market
1.8.1 Global Biologics and Biosimilars Market Status and Outlook (2016-2027)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Biologics and Biosimilars Production Capacity Market Share by Manufacturers (2016-2021)
2.2 Global Biologics and Biosimilars Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Biologics and Biosimilars Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Biologics and Biosimilars Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Biologics and Biosimilars Sales Volume Market Share by Region (2016-2021)
3.2 Global Biologics and Biosimilars Sales Revenue Market Share by Region (2016-2021)
3.3 North America Biologics and Biosimilars Sales Volume
3.3.1 North America Biologics and Biosimilars Sales Volume Growth Rate (2016-2021)
3.3.2 North America Biologics and Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.4 East Asia Biologics and Biosimilars Sales Volume
3.4.1 East Asia Biologics and Biosimilars Sales Volume Growth Rate (2016-2021)
3.4.2 East Asia Biologics and Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.5 Europe Biologics and Biosimilars Sales Volume (2016-2021)
3.5.1 Europe Biologics and Biosimilars Sales Volume Growth Rate (2016-2021)
3.5.2 Europe Biologics and Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.6 South Asia Biologics and Biosimilars Sales Volume (2016-2021)
3.6.1 South Asia Biologics and Biosimilars Sales Volume Growth Rate (2016-2021)
3.6.2 South Asia Biologics and Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.7 Southeast Asia Biologics and Biosimilars Sales Volume (2016-2021)
3.7.1 Southeast Asia Biologics and Biosimilars Sales Volume Growth Rate (2016-2021)
3.7.2 Southeast Asia Biologics and Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.8 Middle East Biologics and Biosimilars Sales Volume (2016-2021)
3.8.1 Middle East Biologics and Biosimilars Sales Volume Growth Rate (2016-2021)
3.8.2 Middle East Biologics and Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.9 Africa Biologics and Biosimilars Sales Volume (2016-2021)
3.9.1 Africa Biologics and Biosimilars Sales Volume Growth Rate (2016-2021)
3.9.2 Africa Biologics and Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.10 Oceania Biologics and Biosimilars Sales Volume (2016-2021)
3.10.1 Oceania Biologics and Biosimilars Sales Volume Growth Rate (2016-2021)
3.10.2 Oceania Biologics and Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.11 South America Biologics and Biosimilars Sales Volume (2016-2021)
3.11.1 South America Biologics and Biosimilars Sales Volume Growth Rate (2016-2021)
3.11.2 South America Biologics and Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.12 Rest of the World Biologics and Biosimilars Sales Volume (2016-2021)
3.12.1 Rest of the World Biologics and Biosimilars Sales Volume Growth Rate (2016-2021)
3.12.2 Rest of the World Biologics and Biosimilars Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
4 North America
4.1 North America Biologics and Biosimilars Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Biologics and Biosimilars Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Biologics and Biosimilars Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Biologics and Biosimilars Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Biologics and Biosimilars Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Biologics and Biosimilars Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Biologics and Biosimilars Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Biologics and Biosimilars Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Biologics and Biosimilars Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Biologics and Biosimilars Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Biologics and Biosimilars Sales Volume Market Share by Type (2016-2021)
14.2 Global Biologics and Biosimilars Sales Revenue Market Share by Type (2016-2021)
14.3 Global Biologics and Biosimilars Sales Price by Type (2016-2021)
15 Consumption Analysis by Application
15.1 Global Biologics and Biosimilars Consumption Volume by Application (2016-2021)
15.2 Global Biologics and Biosimilars Consumption Value by Application (2016-2021)
16 Company Profiles and Key Figures in Biologics and Biosimilars Business
16.1 Roche
16.1.1 Roche Company Profile
16.1.2 Roche Biologics and Biosimilars Product Specification
16.1.3 Roche Biologics and Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.2 Amgen
16.2.1 Amgen Company Profile
16.2.2 Amgen Biologics and Biosimilars Product Specification
16.2.3 Amgen Biologics and Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.3 AbbVie
16.3.1 AbbVie Company Profile
16.3.2 AbbVie Biologics and Biosimilars Product Specification
16.3.3 AbbVie Biologics and Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.4 Sanofi-Aventis
16.4.1 Sanofi-Aventis Company Profile
16.4.2 Sanofi-Aventis Biologics and Biosimilars Product Specification
16.4.3 Sanofi-Aventis Biologics and Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.5 Johnson & Johnson
16.5.1 Johnson & Johnson Company Profile
16.5.2 Johnson & Johnson Biologics and Biosimilars Product Specification
16.5.3 Johnson & Johnson Biologics and Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.6 Pfizer
16.6.1 Pfizer Company Profile
16.6.2 Pfizer Biologics and Biosimilars Product Specification
16.6.3 Pfizer Biologics and Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.7 Novo Nordisk
16.7.1 Novo Nordisk Company Profile
16.7.2 Novo Nordisk Biologics and Biosimilars Product Specification
16.7.3 Novo Nordisk Biologics and Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.8 Eli Lilly
16.8.1 Eli Lilly Company Profile
16.8.2 Eli Lilly Biologics and Biosimilars Product Specification
16.8.3 Eli Lilly Biologics and Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.9 Novartis
16.9.1 Novartis Company Profile
16.9.2 Novartis Biologics and Biosimilars Product Specification
16.9.3 Novartis Biologics and Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.10 Merck
16.10.1 Merck Company Profile
16.10.2 Merck Biologics and Biosimilars Product Specification
16.10.3 Merck Biologics and Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.11 3sbio
16.11.1 3sbio Company Profile
16.11.2 3sbio Biologics and Biosimilars Product Specification
16.11.3 3sbio Biologics and Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.12 Changchun High Tech
16.12.1 Changchun High Tech Company Profile
16.12.2 Changchun High Tech Biologics and Biosimilars Product Specification
16.12.3 Changchun High Tech Biologics and Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.13 CP Guojian
16.13.1 CP Guojian Company Profile
16.13.2 CP Guojian Biologics and Biosimilars Product Specification
16.13.3 CP Guojian Biologics and Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.14 Biotech
16.14.1 Biotech Company Profile
16.14.2 Biotech Biologics and Biosimilars Product Specification
16.14.3 Biotech Biologics and Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.15 Gelgen
16.15.1 Gelgen Company Profile
16.15.2 Gelgen Biologics and Biosimilars Product Specification
16.15.3 Gelgen Biologics and Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.16 Innovent
16.16.1 Innovent Company Profile
16.16.2 Innovent Biologics and Biosimilars Product Specification
16.16.3 Innovent Biologics and Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.17 Dong Bao
16.17.1 Dong Bao Company Profile
16.17.2 Dong Bao Biologics and Biosimilars Product Specification
16.17.3 Dong Bao Biologics and Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.18 Ganlee
16.18.1 Ganlee Company Profile
16.18.2 Ganlee Biologics and Biosimilars Product Specification
16.18.3 Ganlee Biologics and Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.19 United Laboratories
16.19.1 United Laboratories Company Profile
16.19.2 United Laboratories Biologics and Biosimilars Product Specification
16.19.3 United Laboratories Biologics and Biosimilars Production Capacity, Revenue, Price and Gross Margin (2016-2021)
17 Biologics and Biosimilars Manufacturing Cost Analysis
17.1 Biologics and Biosimilars Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Biologics and Biosimilars
17.4 Biologics and Biosimilars Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Biologics and Biosimilars Distributors List
18.3 Biologics and Biosimilars Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Biologics and Biosimilars (2022-2027)
20.2 Global Forecasted Revenue of Biologics and Biosimilars (2022-2027)
20.3 Global Forecasted Price of Biologics and Biosimilars (2016-2027)
20.4 Global Forecasted Production of Biologics and Biosimilars by Region (2022-2027)
20.4.1 North America Biologics and Biosimilars Production, Revenue Forecast (2022-2027)
20.4.2 East Asia Biologics and Biosimilars Production, Revenue Forecast (2022-2027)
20.4.3 Europe Biologics and Biosimilars Production, Revenue Forecast (2022-2027)
20.4.4 South Asia Biologics and Biosimilars Production, Revenue Forecast (2022-2027)
20.4.5 Southeast Asia Biologics and Biosimilars Production, Revenue Forecast (2022-2027)
20.4.6 Middle East Biologics and Biosimilars Production, Revenue Forecast (2022-2027)
20.4.7 Africa Biologics and Biosimilars Production, Revenue Forecast (2022-2027)
20.4.8 Oceania Biologics and Biosimilars Production, Revenue Forecast (2022-2027)
20.4.9 South America Biologics and Biosimilars Production, Revenue Forecast (2022-2027)
20.4.10 Rest of the World Biologics and Biosimilars Production, Revenue Forecast (2022-2027)
20.5 Forecast by Type and by Application (2022-2027)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2022-2027)
20.5.2 Global Forecasted Consumption of Biologics and Biosimilars by Application (2022-2027)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Biologics and Biosimilars by Country
21.2 East Asia Market Forecasted Consumption of Biologics and Biosimilars by Country
21.3 Europe Market Forecasted Consumption of Biologics and Biosimilars by Countriy
21.4 South Asia Forecasted Consumption of Biologics and Biosimilars by Country
21.5 Southeast Asia Forecasted Consumption of Biologics and Biosimilars by Country
21.6 Middle East Forecasted Consumption of Biologics and Biosimilars by Country
21.7 Africa Forecasted Consumption of Biologics and Biosimilars by Country
21.8 Oceania Forecasted Consumption of Biologics and Biosimilars by Country
21.9 South America Forecasted Consumption of Biologics and Biosimilars by Country
21.10 Rest of the world Forecasted Consumption of Biologics and Biosimilars by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer
